Results: 3 RCTs contained data regarding mRSS at week 12 of treatment with Rituximab. The estimated SMD was -1.071 (95% CI -1.608, -0.535 [p < 0.001]) with a non-significant P value in the Egger Test (P = 0.703) and non-significant heterogeneity through I2 (I2 = 0.00%). 9 studies contained data regarding mRSS at week 24 of treatment with Rituximab. The estimated SMD was -1.743 (CI95% -2.622, -0.864 [p < 0.001], see image below) with a non-significant P value in the Egger Test (P = 0.072) and significant heterogeneity through I2 (I2 = 86.6%). Meta-regression analysis could not be performed to assess such heterogeneity, due to the lack of comparable data.

8 RCTs contained data regarding mRSS at week 48 of Rituximab treatment. The estimated SMD was -1.327 (CI95% -2.018, -0.636 [p < 0.001]) with a significant P value in the Egger Test (P = 0.018), estimating that there may be publication bias in the studies analyzed and significant heterogeneity by I2 (I2 = 85.2%). Meta-regression analysis could not be performed to assess such heterogeneity, due to the lack of comparable data.

Conclusion: Our meta-analysis shows that Rituximab treatment in patients affected with systemic sclerosis shows efficacy in the treatment of cutaneous fibrosis measured by the mRSS, turning this molecule into a potential drug to add to the therapeutic armamentarium of systemic sclerosis. However, more studies are necessary to try to elucidate whether this change is powerful enough to become the new gold standard for the treatment of systemic sclerosis skin involvement.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.3161

POS0874
CLOT LYYSIS TIME PREDICTS RECURRENT DIGITAL ULCERS IN SYSTEMIC SCLEROSIS AFTER ONE YEAR OF FOLLOW-UP: A NESTED CASE-CONTROL STUDY

J. Colicí, A. Antovic, J. Pruner, J. Vojnovic, N. Damjanov, M. Sefik Buklica, M. Institute of Rheumatology, Department of Rheumatology Ivb Unit, Belgrade, Serbia; Karolinska Institutet, Karolinska University Hospital Solna, Department of Medicine, Rheumatology Unit, Stockholm, Sweden; Karolinska Institute, Department of Molecular Medicine and Surgery, Stockholm, Sweden; Medical Faculty, University of Niš, Department of Pediatrics, Niš, Serbia; School of Medicine, University of Belgrade, Internal Medicine, Belgrade, Serbia; Institute of Rheumatology, Department of Rheumatology Unit, Belgrade, Serbia

Background: Digital ulcers (DU) are a common visible manifestation of vasculopathy in systemic sclerosis (SSc), which could be recurrent and associated with disability and mortality (1). Although vasculopathy is connected with impaired coagulation/fibrinolysis parameters and aberration of adherence molecules, there are few data about their role in developing recurrent DU.

Objectives: To evaluate the possible role of Fibrin generation/Fibrinolysis parameters and adhesion molecules in the prediction of new ischaemic DU onset during a 1-year follow-up and their impact on the time to new DU onset (TD).

Methods: From 58 consecutive patients with SSc who fulfilled the 2013 ACR/ EULAR SSc criteria and have never been treated with endothelin receptor antagonists, phosphodiesterase 5 inhibitors or prostanoids, a total of 38 patients with ever had DU, either active at inclusion or in past, were enrolled in a prospective cohort study. Each patient was given a “DU diary”; Demographic, clinical and serological data were recorded. The serum concentration of ICAM1 and E selectin were measured by ELISA. Haemostatic potential parameters: overall haemostasis (OHP), overall coagulation (OCP) and overall fibrinolysis (OFP) potential were assessed. Maximum absorbance (Cmax), reflects the fibrin clot density and clot lysis time (Lys50t0, time from initiation of clot formation to the time at which a 50% fall in absorbance from Cmax in the lysis assay), reflects fibrinolytic susceptibility, were calculated (2). Fibrin structure was visualised using scanning electron microscopy (SEM).

Results: Over the follow-up period, 18 patients (45.5%) developed new DU with the average TD of 7.4±2.9 months. There was no difference in ASA and CCB treatment among two groups (p>0.05). The OFF value was significantly decreased (p<0.01), Lys50t0 prolonged (p<0.05), while OHP was increased (p<0.05) in patients experienced new DU. Lys50t0 showed good validity in identifying patients with new DU onset (AUC 0.683 95% CI 0.5 - 0.9). By multivariate analysis including clinical data in model the Lys50t0 (HR 1.2, 95% CI 1.1-1.3, p = 0.018) and active DU at enrollment (HR 9.6, 95% CI 1.4-66.8, p = 0.022) were identified as independent risk factors for the occurrence of new DU. TD was inversely correlated with ICAM1(p<0.001), E selectin (p<0.05), Cmax (p<0.05) and Lys50t0 (p<0.01). Model explaining 81.6% of the TD variability included Lys50t0 (β = -0.55, p=0.003), E selectin (β = -0.44, p=0.014) and fibrinogen (β = -0.40, p=0.017). SEM revealed denser fibrin clots with thinner fibres in group experienced new DU compared to clots formed in plasma of patient without DU.

Conclusion: This results provide evidence that impaired fibrinolysis has critical role in the progression of microvascular disease, identifying clot lysis time as a strong predictor in the onset of new digital ulcers in Systemic sclerosis. The higher level of E selectin and the longer lysis time are, the shorter is time until the onset of new digital ulcer. These results could be used in selection of patients at high risk of developing recurrent digital ulcer and therefore allow earlier therapeutic intervention.

REFERENCES:

Figure 1. SEM images of fibrin network in 1 representative sample from a SSc patient with (A) and from patient without (B) new DU onset.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.3163

POS0875
MYOSITIS-SPECIFIC ANTIBODIES IN A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY

J. Álvarez-Troncoso, S. Carrasco Molina, J. Valdivieso, P. Nozal, A. Robles Marhuenda, E. Martínez Robles, C. Soto Abadíes, J. J. Rios, A. Noblejas Mozó, F. Arnalché Fernández, Hospital Universitario La Paz, Internal Medicine, Madrid, Spain; Hospital Universitario La Paz, Clinical Immunology, Madrid, Spain

Background: Myositis-specific antibodies (MSA) are highly specific and useful to classify patients as having syndromes with distinct clinical features and prognosis. MSA are almost always mutually exclusive and quite specific, adding value as a useful biomarker for diagnosis. Although individual autoantibodies aren’t sensitive enough to detect the full spectrum of idiopathic inflammatory myopathies (IIM), the sensitivity of a myositis panel is increasing as more autoantibodies are discovered, and as better assays become available.

Objectives: We aimed to analyze the usefulness of a myositis-specific immunoblot for the diagnosis of IIM in a hospital cohort from January 2019 to December 2020. We also seek to correlate immunological findings with the risk of associated interstitial lung disease (ILD), cancer, or death.
Cancer was found in 9.6% of MSA+ve patients. The most frequent tumors were gynecological (37.5%), followed by gastrointestinal (25%) and breast cancer (12.5%). Factors associated with cancer were age (p=0.010), TIF1-γ (ρ=0.001), SRF (p=0.004), PL-12 (p=0.013), PL-7 (p=0.047) and HMGR (p=0.027). The mortality of these patients was 3.5%. There were no differences regarding MSA+ve vs MSA-ve (p = 0.991). However, MDA-5 (p=0.033) and older age (p=0.001) were associated with higher mortality. There were no significant differences between the IIM classifications, the associated SAD, the presence of cancer or ILD. However, longer follow-up periods and future studies are necessary to confirm these results.

Conclusion: The use of a myositis blot allowed classifying, stratifying the risk of ILD, the risk of cancer and the risk of mortality in IIM. IIM-ILD was the most frequent complication, usually manifested as NSIP. The associated risk factors were ARS, OM, some MSAs, Ro52+ and older age. Cancer was a serious and frequent manifestation in these patients, especially in patients with TIF1-γ and other MSAs, so it is essential to know the risk factors and perform an early screening, especially in older patients.

A better knowledge of the serological profiles of IIM will provide more individualized approaches and better risk stratification, helping in the management and treatment of these patients.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3248